Patient Preferences in the Management of Hidradenitis Suppurativa: Results of a Multinational Discrete Choice Experiment in Europe

Damon Willems*, Eva Lotta Hinzpeter, Hessel H. Van der Zee, Christopher J. Sayed, John R. Ingram, Charlotte Beaudart, Silvia M.A.A. Evers, Mickael Hiligsmann

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)
31 Downloads (Pure)


Background and Objective: Hidradenitis suppurativa is a chronic inflammatory skin disease that can lead to a substantial reduction in quality of life. Recent studies revealed high levels of unmet care needs of patients with hidradenitis suppurativa, but their preferences in treatment decision making have scarcely been investigated. This study aimed to reveal which treatment attributes adult patients with HS in Europe consider most important in treatment decision-making. Methods: A discrete choice experiment was conducted with adult patients with hidradenitis suppurativa in Europe to reveal which treatment attributes are most important when making treatment decisions. Participants were presented with 15 sets of two treatment options and asked for each to choose the treatment they preferred. The treatments were characterized by six attributes informed by a prior literature review and qualitative research: effectiveness, pain reduction, duration of treatment benefit, risk of mild adverse event, risk of serious infection, and mode of administration. A random parameter logit model was used to estimate patients’ preferences with additional subgroup and latent class models used to explore any differences in preferences across patient groups. Results: Two hundred and nineteen adult patients with hidradenitis suppurativa were included in the analysis (90% women, mean age 38 years). For all six treatment attributes, significant differences were observed between levels. Given the range of levels of each attribute, the most important treatment attributes were effectiveness (47.9%), followed by pain reduction (17.3%), annual risk of a mild adverse event (14.4%), annual risk of a serious infection (10.3%), mode of administration (5.3%), and duration of treatment benefit (4.8%). Higher levels of effectiveness, namely a 75% or 100% reduction in the abscess and inflammatory nodule count, were preferred over levels of effectiveness primarily investigated in randomized clinical trials of hidradenitis suppurativa (a 50% reduction). Results were largely consistent across subgroups and three latent class groups were identified. Conclusions: This study revealed the most important treatment characteristics for patients with hidradenitis suppurativa that can help inform joint patient-physician decision making in the management of hidradenitis suppurativa. Designing future hidradenitis suppurativa treatments according to stated preferences, namely, to offer higher levels of effectiveness and pain improvement without higher risks of adverse events, may increase patients’ treatment concordance and lead to improved disease management outcomes.

Original languageEnglish
Pages (from-to)153-164
Number of pages12
Issue number2
Publication statusPublished - Mar 2023

Bibliographical note

Funding Information:
The authors thank the participants for completing the survey. The authors also thank the patient organizations (Hidradenitis Patiënten Vereniging Nederland, Verein Acne Inversa SchwAIz, Irish Skin, and Patientforeningen HS Danmark) that supported this research with the invitation of participants.

Publisher Copyright:
© 2023, The Author(s).


Dive into the research topics of 'Patient Preferences in the Management of Hidradenitis Suppurativa: Results of a Multinational Discrete Choice Experiment in Europe'. Together they form a unique fingerprint.

Cite this